title: Elevated serum titers of proinflammatory cytokines and CNS autoantibodies in patients with chronic spinal cord injury.
abstract: This study characterized the proinflammatory cytokines, interleukin-2 (IL-2) and tumor necrosis factor alpha (TNFalpha), the antiinflammatory cytokines, IL-4 and IL-10, autoantibodies specific for GM1 ganglioside (anti-GM1), IgG and IgM, and myelin-associated glycoprotein (anti-MAG), in the sera of infection-free, chronic (>12 months), traumatically injured SCI patients (n = 24). Healthy able-bodied subjects (n = 26) served as controls. The proinflammatory cytokines and anti-GM1 antibodies were of particular interest as they have been implicated in an autoimmune "channelopathy" component to central and peripheral conduction deficits in various chronic neuroinflammatory diseases. Antibody and cytokine titers were established using enzyme-linked immunosorbent assays (ELISA). The mean anti-GM(1) (IgM) titer value for the SCI group was significantly higher (p < 0.05) than controls. The SCI group also demonstrated significantly higher titers (p < 0.05) of IL-2 and TNF alpha than controls. No differences were found between the SCI group and control group mean levels of IL-4 or IL-10. Overall, the serum of 57% of SCI patients contained increased levels of autoantibodies or proinflammatory cytokines relative to control values. These results provide preliminary support for the hypothesis that chronic immunological activation in the periphery occurs in a subpopulation of chronic SCI patients. It remains to be established whether elevated serum titers of proinflammatory cytokines and autoantibodies against GM1 are beneficial to the patients or whether they are surrogate markers of a channelopathy that compounds the neurological impairment associated with traumatic axonopathy or myelinopathy.
authors.affiliation: Department of Physical Medicine and Rehabilitation, University of Western Ontario, and Lawson Health Research Institute, St. Joseph's Health Care London, London, Ontario, Canada. kchayes@julian.uwo.ca
authors.forename: K C
authors.initials: KC
authors.lastname: Hayes
authors.forename: T C L
authors.initials: TC
authors.lastname: Hull
authors.forename: G A
authors.initials: GA
authors.lastname: Delaney
authors.forename: P J
authors.initials: PJ
authors.lastname: Potter
authors.forename: K A J
authors.initials: KA
authors.lastname: Sequeira
authors.forename: K
authors.initials: K
authors.lastname: Campbell
authors.forename: P G
authors.initials: PG
authors.lastname: Popovich
mesh_terms: D000328:Adult; D001323:Autoantibodies / Q000097:blood*; D001402:B-Lymphocytes / Q000276:immunology; D002908:Chronic Disease; D005260:Female; D005677:G(M1) Ganglioside / Q000276:immunology; D006801:Humans; D016753:Interleukin-10 / Q000097:blood; D007376:Interleukin-2 / Q000097:blood*; D015847:Interleukin-4 / Q000097:blood; D008297:Male; D008875:Middle Aged; D018992:Myelin-Associated Glycoprotein / Q000276:immunology; D013119:Spinal Cord Injuries / Q000097:blood* / Q000276:immunology*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
chemical_list: D001323:Autoantibodies; D007376:Interleukin-2; D018992:Myelin-Associated Glycoprotein; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D015847:Interleukin-4; D005677:G(M1) Ganglioside